RTP Mobile Logo

In these audio proceedings from a closed Think Tank meeting held in November 2013, the invited faculty discuss and debate some of the key clinical management issues in lung cancer as well as promising research strategies in this area. The roundtable discussion focused on key presentations and papers and actual cases managed in the practices of the faculty in which these data sets factored into their decision-making. This content is available in a number of formats for listening on the go with a mobile device or in the office or at home on a computer.
 

Listen to audio excerpts

Track 1: Case discussion: A 57-year-old Asian patient and never smoker with liver metastases and biopsy-proven non-small cell lung cancer (NSCLC) without sufficient tissue for definitive histology and mutation profiling
Track 2: Appraisal of first-line treatment options for patients with EGFR exon 19 deletion-positive adenocarcinoma of the lung
Track 3: Use of afatinib versus erlotinib as first-line therapy for patients with EGFR mutation-positive disease
Track 4: Viewpoints on continuation of erlotinib after disease progression in patients with advanced, EGFR-mutant NSCLC
Track 5: Approach to maintenance therapy for patients with advanced, EGFR-mutant NSCLC
Track 6: First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor (TKI) of EGFR-activating and T790M mutations
Track 7: Erlotinib Beyond Progression study: Results of a Phase II trial comparing chemotherapy in combination with erlotinib to chemotherapy alone in EGFR TKI-responsive NSCLC that subsequently progresses
Track 8: Genomic landscape of EGFR mutations in NSCLC
Track 9: Response to erlotinib and prognosis for patients with de novo EGFR T790M mutations
Track 10: Activity of afatinib in patients with uncommon EGFR mutations on the LUX-Lung 2, 3 and 6 trials
Track 11: Case discussion: A 55-year-old nonsmoker who previously underwent treatment for EGFR wild-type, Stage III adenocarcinoma of the lung is found to harbor an ALK translocation and experiences a near-complete response with crizotinib followed by progression and then response to LDK378
Track 12: Activity of the second-generation investigational ALK inhibitor LDK378
Track 13: Therapeutic strategies to overcome crizotinib resistance
Track 14: Clinical activity of the ALK inhibitor LDK378 in crizotinib-naïve and crizotinib-resistant advanced, ALK mutation-positive NSCLC
Track 15: Use of dose attenuations of LDK378 for patients with AST/ALT elevations
Track 16: Activity of the second-generation ALK inhibitor alectinib (CH5424802) for patients with ALK inhibitor-naïve, ALK-rearranged advanced NSCLC
Track 17: Incorporation of second-generation ALK inhibitors into the treatment algorithm for ALK-rearranged, advanced NSCLC
Track 18: Activity and increased specificity of second-generation ALK inhibitors
Track 19: Clinical, pathologic and biologic features associated with BRAF mutations and interim results of the Phase II BRF113928 study of dabrafenib in BRAF V600E mutation-positive NSCLC
Track 20: Ongoing Phase II trial of dasatinib for patients with NSCLC or other advanced solid tumors harboring DDR2 mutation or inactivating BRAF mutation
Track 21: Early data with BRAF inhibitors for BRAF-mutant, advanced NSCLC
Track 22: Results from the Phase III PointBreak trial of pemetrexed, carboplatin and bevacizumab followed by maintenance pemetrexed/bevacizumab versus the ECOG-E4599 regimen for Stage IIIB/IV nonsquamous NSCLC
Track 23: First-line and maintenance therapy for patients with pan-wild-type adenocarcinoma who are eligible to receive bevacizumab
Track 24: ECOG-E5508: A Phase III study of maintenance bevacizumab, pemetrexed or the combination in advanced nonsquamous NSCLC
Track 25: Results of a Phase III trial of pemetrexed in combination with carboplatin → maintenance pemetrexed versus the ECOG-E4599 regimen for advanced nonsquamous NSCLC
Track 26: Case discussion: An 82-year-old former heavy smoker who previously underwent treatment for advanced squamous cell lung carcinoma receives the anti-PD-1 receptor antibody nivolumab on a clinical trial
Track 27: Role of next-generation sequencing in patients with squamous cell carcinoma
Track 28: Response to the anti-PD-1 monoclonal antibody nivolumab on a clinical trial
Track 29: Clinical activity, safety and biomarkers of the anti-PD-L1 antibody MPDL3280A in patients with locally advanced or metastatic NSCLC
Track 30: Tolerability of and “pseudoprogression” with immune checkpoint inhibitors in NSCLC
Track 31: Clinical response to anti-PD-1 and anti-PD-L1 checkpoint inhibitors
Track 32: Ongoing trials of checkpoint inhibitors in previously treated metastatic squamous and nonsquamous NSCLC
Track 33: Forecast for the future development of immune-based therapies in lung cancer
Track 34: Case discussion: An 81-year-old patient who previously underwent treatment for bladder cancer presents with Stage II, KRAS-mutant adenocarcinoma of the lung
Track 35: Critical appraisals of adjuvant chemotherapy options for younger versus older patients
Track 36: Response and side effects of adjuvant cisplatin/vinorelbine in elderly patients
Track 37: Case discussion: A 49-year-old never smoker presents with cough and shortness of breath and is diagnosed with Stage III adenocarcinoma of the lung and an EGFR L858R mutation
Track 38: RTOG-1306: A Phase II trial of individualized combined modality therapy for Stage III NSCLC
Track 39: Perspectives on clinical trials of neoadjuvant erlotinib in EGFR mutation-positive, Stage III NSCLC
Track 40: Results of the Phase II OAM4558g trial of onartuzumab (MetMAb) in combination with erlotinib for advanced NSCLC
Track 41: MetLung (OAM4971g): A Phase III trial of onartuzumab in combination with erlotinib versus placebo with erlotinib for patients with previously treated NSCLC
Track 42: INSPIRE and SQUIRE: Results of Phase III trials of cisplatin/pemetrexed with or without the human IgG1 anti-EGFR antibody necitumumab as first-line therapy for Stage IV nonsquamous and squamous NSCLC, respectively
Track 43: Case discussion: A 64-year-old former smoker with recurrent squamous cell NSCLC 3 months after treatment with carboplatin/paclitaxel receives docetaxel nanoparticles on a clinical trial
Track 44: Role of nanoparticle albumin-bound (nab) paclitaxel in the treatment of advanced squamous cell carcinoma of the lung
Track 45: Perspectives on the use of the VeriStrat® assay
Track 46: Results of PROSE: A Phase III trial of proteomic-stratified (VeriStrat) second-line erlotinib versus chemotherapy for patients with inoperable NSCLC
Track 47: Viewpoints on tolerability and quality of life with erlotinib versus chemotherapy for NSCLC
 
FACULTY:
 
Chandra P Belani, MD
Miriam Beckner Distinguished
Professor of Medicine
Penn State College of Medicine
Deputy Director
Penn State Hershey Cancer Institute
Hershey, Pennsylvania
 
Ramaswamy Govindan, MD
Professor of Medicine
Co-Director, Section of
Medical Oncology
Division of Oncology
Washington University
School of Medicine
St Louis, Missouri
 
John V Heymach, MD, PhD
Professor and Chair
Thoracic/Head and Neck
Medical Oncology
The University of Texas
MD Anderson Cancer Center
Houston, Texas
 
Gregory J Riely, MD, PhD
Assistant Attending
Memorial Sloan-Kettering
Cancer Center
Assistant Professor
Weill Cornell Medical College
New York, New York
 
Mark A Socinski, MD
Professor of Medicine and
Thoracic Surgery
Director, Lung Cancer Section
Division of Hematology/Oncology
Co-Director, UPMC Lung Cancer
Center of Excellence
Co-Director
Lung and Thoracic
Malignancies Program
University of Pittsburgh
UPMC Cancer Pavilion
Pittsburgh, Pennsylvania
 
David R Spigel, MD
Program Director
Lung Cancer Research
Sarah Cannon Research Institute
Nashville, Tennessee
 
MODERATOR:
 
Neil Love, MD
Research To Practice
Miami, Florida